Healthcare
NovaBridge Biosciences(NBP)
Live Price
Offline$1.50
-4.46% today
1Y Change
-46.04%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $1.87B
- Revenue Growth
- 0.0%
- EPS Growth
- +75.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
NovaBridge Biosciences (NBP) is a Healthcare stock with a market cap of $1.87B and listed on NASDAQ. The stock last traded around $1.50 and down 46.0% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +75.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +75.3%, free cash flow +60.9% with operating margin 0.0% and ROIC -40.3%. Stock Foundry combines NBP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 2, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +75.3%, while operating margin sits near 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Jun 30, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 2, 2026 | โ | -0.4% | -2.9% | -2.1% |
2025 Dec 18, 2025 | -1801.1% | +5.8% | +9.6% | -4.3% |
2025 Nov 12, 2025 | +76.5% | -1.2% | +7.3% | -7.1% |
Benchmark Edge
NBP vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NBP
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NBP Max Drawdown
-77.59%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NBP and SPY.
Company Overview
NovaBridge Biosciences
NASDAQ Global Market
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
- Leadership
- Xi-Yong Fu
- IPO Date
- Jan 17, 2020
- Employees
- 32
- Street Address
- 2440 Research Boulevard
- Mailing
- Rockville, MD, 20850
- Region
- Rockville, MD, US
- Reporting Currency
- USD
- Investor Line
- 240 745 6330
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.5
Growth
- Revenue
- 0.0%
- EPS
- +75.3%
- Free Cash Flow
- +60.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -7.5%
- ROIC
- -40.3%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 8.09
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.